Antitumor activity of DNA vaccines based on the human papillomavirus-16 E7 protein genetically fused to a plant virus coat protein

Human Gene Therapy

Volumn 19, Issue 4, 2008, Pages 354-364

  Massa, Silvia ^a   Simeone, Paola ^b   Muller, Antonio ^b   Benvenuto, Eugenio ^a   Venuti, Aldo ^b   Franconi, Rosella ^a  

^a ENEA C R CASACCIA   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COAT PROTEIN; DNA VACCINE; GAMMA INTERFERON; HYBRID PROTEIN; PLASMID COMPLEMENTARY DNA COAT PROTEIN; PLASMID COMPLEMENTARY DNA E7GGG COAT PROTEIN; PLASMID COMPLEMENTARY DNA E7GGG PROTEIN; PLASMID DNA; PROTEASOME INHIBITOR; PROTEIN E7;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; ARTICLE; C57BL 6 MOUSE; CANCER INHIBITION; CELL STRAIN HEK293; CONTROLLED STUDY; CYTOKINE RELEASE; DNA IMMUNIZATION; DRUG POTENCY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENE FUSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOFLUORESCENCE MICROSCOPY; MOUSE; NONHUMAN; POTEXVIRUS; PROTEIN EXPRESSION; UTERINE CERVIX CARCINOMA;

ANIMALS; ANTIBODIES; ANTIBODY FORMATION; CANCER VACCINES; CAPSID PROTEINS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION; IMMUNITY, CELLULAR; MICE; MICE, INBRED C57BL; ONCOGENE PROTEINS, VIRAL; PROTEASOME ENDOPEPTIDASE COMPLEX; RECOMBINANT FUSION PROTEINS; VACCINES, DNA;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS - 16; HUMAN PAPILLOMAVIRUS TYPE 16; MAMMALIA; MUS; POTATO VIRUS X;

EID: 42549113461     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2007.122     Document Type: Article

References (46)

1. + T cell-dependent protection. Eur. J. Immunol. 37, 376-384.
2. CAÑIZARES, M.C., NICHOLSON, L., and LOMONOSSOFF, G.P. (2005). Use of viral vectors for vaccine production in plants. Immunol. Cell Biol. 83, 263-270.
3. CHEN, C.H., WANG, T.L., HUNG, C.F., YANG, Y., YOUNG, R.A., PARDOLL, D.M., and WU, T.C. (2000). Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res. 60, 1035-1042.
4. CHENG, W.F., HUNG, C.F., CHAI, C.Y., HSU, K.F., HE, L., LING, M., and WU, T.C. (2001). Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J. Clin. Invest. 108, 669-678.
5. CHENG, W.F., HUNG, C.F., PAI, S.I., HSU, K.F., HE, L., LING, M., and WU, T.C. (2002). Repeated DNA vaccinations elicited qualitatively different cytotoxic T lymphocytes and improved protective antitumor effects. J. Biomed. Sci. 9, 675-687.
6. CRUZ, S.S., CHAPMAN, S., ROBERTS, A.G., ROBERTS, I.M., PRIOR, D.A., and OPARKA, K.J. (1996). Assembly and movement of a plant virus carrying a green fluorescent protein overcoat. Proc. Natl. Acad. Sci. U.S.A. 93, 6286-6290.
7. DE MARCO, F., HALLEZ, S., BRULET, J.M., GESCHE, F., MARZANO, P., FLAMINI, S., MARCANTE, M.L., and VENUTI, A. (2003). DNA vaccines against HPV-16 E7-expressing tumour cells. Anticancer Res. 23, 1449-1454.
8. DOAN, T., HERD, K.A., LAMBERT, P.F., FERNANDO, G.J., STREET, M.D., and TINDLE, R.W. (2000). Peripheral tolerance to human papillomavirus E7 oncoprotein occurs by cross-tolerization, is largely Th-2-independent, and is broken by dendritic cell immunization. Cancer Res. 60, 2810-2815.
9. EGGLETON, P., and LLEWELLYN, D.H. (1999). Pathophysiological roles of calreticulin in autoimmune disease. Scand. J. Immunol. 49, 466-473.
10. EIBEN, G.L., VELDERS, M.P., and KAST, W.M. (2002). The cell-mediated immune response to human papillomavirus-induced cervical cancer: Implications for immunotherapy. Adv. Cancer Res. 86, 113-148.
11. FERLAY, J., BRAY, F., PISANI, P., and PARKIN, D.M. (2004). GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. 5, version 2.0 (IARC Press, Lyon, France).
12. FRANCONI, R., DI BONITO, P., DIBELLO, F., ACCARDI, L., MULLER, A., CIRILLI, A., SIMEONE, P., DONÀ, M.G., VENUTI, A., and GIORGI, C. (2002). Plant-derived human papillomavirus 16 E7 oncoprotein induces immune response and specific tumor protection. Cancer Res. 62, 3654-3658.
13. FRAZER, I.H. (2004). Prevention of cervical cancer through papillomavirus vaccination. Nat. Rev. Immunol. 4, 46-54.
14. GERLONI, M., XIONG, S., MUKERJEE, S., SCHOENBERGER, S.P., CROFT, M., and ZANETTI, M. (2000). Functional cooperation between T-helper cell determinants. Proc. Natl. Acad. Sci. U.S.A. 97, 13269-13274.
15. HARPER, D.M., FRANCO, E.L., WHEELER, C.M., MOSCICKI, A.B., ROMANOWSKI, B., ROTELI-MARTINS, C.M., JENKINS, D., SCHUIND, A., COSTA CLEMENS, S.A., and DUBIN, G. (2006). Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet 367, 1247-1255.
16. HSU, K.F., HUNG, C.F., CHENG, W.F., HE, L., SLATER, L.A., LING, M., and WU, T.C. (2001). Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther. 8, 376-383.
17. HUNG, C.F., CHENG, W.F., HSU, K.F., CHAI, C.Y., HE, L., LING, M., and WU, T.C. (2001). Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res. 61, 3698-3703.
18. + T cells in the antitumor immune response. J. Exp. Med. 188, 2357-2368.
19. INTERNATIONAL AGENCY FOR RESEARCH ON CANCER. (2005). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 90: Human Papillomavirus. (WHO Press, Geneva, Switzerland).
20. KANG, T.H., LEE, J.H., BAE, H.C., NOH, K.H., KIM, J.H., SONG, C.K., SHIN, B.C., HUNG, C.F., WU, T.C., PARK, J.S., and KIM, T.W. (2006). Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments. Immunol. Lett. 106, 126-134.
21. KOUTSKY, L.A., AULT, K.A., WHEELER, C.M., BROWN, D.R., BARR, E., ALVAREZ, F.B., CHIACCHIERINI, L.M., and JANSEN, K.U. (2002). A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347, 1645-1651.
22. MARUSIC, C., RIZZA, P., LATTANZI, L., MANCINI, C., SPADA, M., BELARDELLI, F., BENVENUTO, E., and CAPONE, I. (2001). Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1. J. Virol. 75, 8434-8439.
23. MILLAR, D.G., GARZA, K.M., ODERMATT, B., ELFORD, A.R., ONO, N., LI, Z., and OHASHI, P.S. (2003). Hsp70 promotes antigen-presenting cell function and converts T-cell tolerance to autoimmunity in vivo. Nat. Med. 9, 1469-1476.
24. + T cells using an ELISPOT assay. J. Immunol. Methods 181, 45-54.
25. MONIZ, M., LING, M., HUNG, C.F., and WU, T.C. (2003). HPV DNA vaccines. Front. Biosci. 8, 55-68.
26. MUNGER, K., BASILE, J.R., DUENSING, S., EICHTEN, A., GONZALEZ, S.L., GRACE, M., and ZACNY, V.L. (2001). Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 20, 7888-7898.
27. MUNGER, K., BALDWIN, A., EDWARDS, K.M., HAYAKAWA, H., NGUYEN, C.L., OWENS, M., GRACE, M., and HUH, K. (2004). Mechanisms of human papillomavirus-induced oncogenesis. J. Virol. 78, 11451-11460.
28. OHLSCHLAGER, P., PES, M., OSEN, W., DURST, M., SCHNEIDER, A., GISSMANN, L., and KAUFMANN, A.M. (2006). An improved rearranged human papillomavirus type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wild type-specific T cell response. Vaccine 24, 2880-2893.
29. PARDOLL, D. (1998). Cancer vaccines. Nat. Med. 4, 525-531.
30. PARKER, L., KENDALL, A., and STUBBS, G. (2002). Surface features of potato virus X from fiber diffraction. Virology 300, 291-295.
31. PENG, S., TOMSON, T.T., TRIMBLE, C., HE, L., HUNG, C.F., and WU, T.C. (2006). A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects. Gene Ther. 13, 257-265.
32. POKORNA, D., MACKOVA, J., DUSKOVA, M., RITTICH, S., LUDVIKOVA, V., and SMAHEL, M. (2005). Combined immunization with fusion genes of mutated E7 gene of human papillomavirus type 16 did not enhance antitumor effect. J. Gene Med. 7, 696-707.
33. REINSTEIN, E., SCHEFFNER, M., OREN, M., CIECHANOVER, A., and SCHWART, A. (2000). Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: Targeting via ubiquitination of the N-terminal residue. Oncogene 19, 5944-5950.
34. + T-cell mediated immunity against B-cell malignancies. Nat. Biotechnol. 19, 760-764.
35. SAVELYEVA, N., ZHU, D., and STEVENSON, F.K. (2003). Engineering DNA vaccines that include plant virus coat proteins. Biotechnol. Genet. Eng. Rev. 20, 101-114.
36. SCHOLTHOF, H.B., SCHOLTHOF, K.B., and JACKSON, A.O. (1996). Plant virus gene vectors for transient expression of foreign proteins in plants. Annu. Rev. Phytopathol. 34, 299-323.
37. SMAHEL, M., SIMA, P., LUDVIKOVA, V., and VONKA, V. (2001). Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology 281, 231-238.
38. SMAHEL, M., POKORNA, D., MACKOVA, J., and VLASAK, J. (2004). Enhancement of immunogenicity of HPV16 E7 oncogene by fusion with E. coli β-glucuronidase. J. Gene Med. 6, 1092-1101.
39. STEVENSON, F.K., OTTENSMEIER, C.H., JOHNSON, P., ZHU, D., BUCHAN, S.L., MCCANN, K.J., RODDIK, J.S., KING, A.T., MCNICHOLL, F., SAVELYEVA, N., and RICE, J. (2004). DNA vaccines to attack cancer. Proc. Natl. Acad. Sci. U.S.A. 101(Suppl. 2), 14646-14652.
40. STEWART, T.J., SMYTH, M.J., FERNANDO, G.J., FRAZER, I.H., and LEGGATT, G.R. (2003). Inhibition of early tumor growth requires Jα18-positive (natural killer T) cells. Cancer Res. 63, 3058-3060.
41. TINDLE, W.R. (2002). Immune evasion in human papillomavirus-associated cervical cancer. Nat. Rev. Cancer 2, 59-65.
42. VILLA, L.L., COSTA, R.L., PETTA, C.A., ANDRADE, R.P., AULT, K.A., GIULIANO, A.R., WHEELER, C.M., KOUTSKY, L.A., MALM, C., LECHTINEN, M., SKIELDESTAD, F.E., OLSSON, S.E., STEINWALL, M., BROWN, D.R., KURMAN, R.J., RONNET, B.M., STOLER, M.H., FERENCZY, A., HARPER, D.M., TAMMS, G.M., YU, J., LUPINACCI, L., RAILKAR, R., TADDEO, F.J., JANSEN, K.U., ESSER, M.T., SINGS, H.L., SAAH, A.J., and BARR, E. (2005). Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6, 271-278.
43. WOLKERS, M.C., TOEBES, M., OKABE, M., HAANEN, J.B., and SCHUMACHER, T.N. (2002). Optimizing the efficacy of epitope-directed DNA vaccination. J. Immunol. 168, 4998-5004.
44. WU, T.C., GUARNIERI, F.G., STAVELEY-O'CARROLL, K.F., VISCIDI, R.P., LEVITSKY, H.I., HEDRICK, L., CHO, K.R., AUGUST, J.T., and PARDOLL, D.M. (1995). Engineering an intracellular pathway for MHC class II presentation of HPV-16 E7. Proc. Natl. Acad. Sci. U.S.A. 9, 11671-11675.
45. ZUR HAUSEN, H. (2002). Papillomaviruses and cancer: From basic studies to clinical application. Nat. Rev. Cancer 2, 342-350.
46. ZUR HAUSEN, H. (2006). Perspectives of contemporary papillomavirus research. Vaccine 24(Suppl. 3), iii-iv.